Advertisement

Pharmaceutical Research

, 36:160 | Cite as

Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib

  • Sudhakar Rajoria
  • Sarita Rani
  • Dasharath Chaudhari
  • Sanyog Jain
  • Umesh GuptaEmail author
Research Paper

Abstract

Purpose

Bortezomib (BTZ) is a proteasome inhibitor used for multiple myeloma and mantle cell lymphoma treatment. BTZ’s aqueous in solubility is the main hindrance in its successful development as a commercial formulation. The main objective of the present study is to develop and characterize folic acid-glycine-poly-L-lactic acid (FA-Gly4-PLA) based nanoformulation (NPs) to improve solubility and efficacy of BTZ.

Methods

BTZ loaded FA-Gly4-PLA NPs were prepared and characterized for size, zeta potential, in vitro studies such as release, kinetics modeling, hemolytic toxicity, and cell line-based studies (Reactive Oxygen Species: ROS and cytotoxicity).

Results

BTZ loaded NPs (BTZ-loaded FA-Gly4-PLA) and blank NPs (FA-Gly4-PLA) size, zeta, and PDI were found to be 110 ± 8.1 nm, 13.7 ± 1.01 mV, 0.19 ± 0.03 and 198 ± 9.01 nm, 8.63 ± 0.21 mV, 0.21 ± 0.08 respectively. The percent encapsulation efficiency (% EE) and percent drug loading (% DL) of BTZ loaded FA-Gly4-PLA NPs was calculated to be 78.3 ± 4.1 and 12.38 ± 2.1. The Scanning Electron Microscopy (SEM) showed that NPs were slightly biconcave in shape. The in vitro release of BTZ from FA-Gly4-PLA NPs resulted in the sustained manner. The prepared NPs were less hemolytic than BTZ.

Conclusions

BTZ loaded Gly4-PLA NPs apoptotic index was found to be much higher than BTZ but lesser than BTZ loaded FA-Gly4-PLA against breast cancer cell lines (MDA-MB-231). ROS intracellular assessment assay indicated that BTZ and BTZ loaded FA-Gly4-PLA NPs exhibited higher ROS production. Conclusively, the BTZ loaded FA-Gly4-PLA NPs were able to encapsulate more BTZ than BTZ loaded Gly4-PLA NPs and were found to be more effective as per as in vitro anti-cancer effect is concerned.

Key words

bortezomib (BTZ) drug delivery folic acid (FA) glycine nanoparticles (NPs) 

Abbreviations

AFM

Atomic Force Microscopy

BTZ

Bortezomib

CLSM

Confocal laser microscope

EDA

Ethylene diamine

ER

Estrogen receptors

FA

Folic acid

Gly

Glycine

HER

Human epidermal growth factor receptor

NPs

Nanoparticles

PDI

Polydispersity Index

PLA

Poly-L-lactic acid

SEM

Scanning Electron Microscopy

TNBC

Triple Negative breast cancer

Notes

Acknowledgments and Disclosures

The authors would like to acknowledge the financial support received from Department of Science and Technology and University Grants Commission, New Delhi, India to Dr. Umesh Gupta in the form of DST Startup Research Grant (for Young Scientists).

Supplementary material

11095_2019_2686_MOESM1_ESM.docx (157 kb)
ESM 1 (DOCX 157 kb)

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefGoogle Scholar
  2. 2.
    Medela S, Syrovab Z, Kovacik L, Hrdy J, Hornacek M, Jager E, et al. Curcumin-bortezomib loaded polymeric nanoparticles for synergistic cancer therapy. Eur Polym J. 2017;93:116–31.CrossRefGoogle Scholar
  3. 3.
    Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239–53.CrossRefGoogle Scholar
  4. 4.
    Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, De Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74.CrossRefGoogle Scholar
  5. 5.
    Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108–21.CrossRefGoogle Scholar
  6. 6.
    Adams J, Palombella VJ, Sausville EA. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–22.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349–60.CrossRefGoogle Scholar
  8. 8.
    Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, et al. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist. 2002;5:249–58.CrossRefGoogle Scholar
  9. 9.
    Nowsheen S, Aziz K, Tran PT. Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett. 2014;2:213–22.CrossRefGoogle Scholar
  10. 10.
    Maynadier M, Basile I, Gallu AD, Gary-Bobo ML, Garcia M. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer. Oncol Rep. 2016;36:1127–34.CrossRefGoogle Scholar
  11. 11.
    Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. Int J Cancer. 2015;13:686–97.CrossRefGoogle Scholar
  12. 12.
    Thaler S, Schmidt M, Roßwag S, Thiede G, Schad A, Jonathan P, et al. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget. 2017;8:72281–301.CrossRefGoogle Scholar
  13. 13.
    Xia X, Liao Y, Guo Z, Li Y, Jiang L, Zhang F, et al. Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer. Oncogenesis. 2018;7:75.CrossRefGoogle Scholar
  14. 14.
    Rose ML, Rusyn I, Bojes HK, Germolec DR, Luster M, Thurman RG, et al. Role of kupffer cells in peroxisome proliferator-induced hepatocyte proliferation. Drug Metab Rev. 1999;31:87–116.CrossRefGoogle Scholar
  15. 15.
    Rose ML, Madren J, Bunzendahl H, Thurman RG. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis. 1999;20:793–8.CrossRefGoogle Scholar
  16. 16.
    Gomaa AI, Khan SA, Leen ELS. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2001;15:1301–14.CrossRefGoogle Scholar
  17. 17.
    Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86:33–48.CrossRefGoogle Scholar
  18. 18.
    Ahmad A, Fauzia E, Kumar M, Mishra RK, Kumar A, Khan MA, et al. Gelatin-coated polycaprolactone nanoparticle-mediated naringenin delivery rescue human mesenchymal stem cells from oxygen glucose deprivation-induced inflammatory stress. ACS Biomater Sci Eng.  https://doi.org/10.1021/acsbiomaterials8b01081.
  19. 19.
    Antonakakis S, Sarantopoulou N, Trohopoulos E, Stefi PN, Kollia AL, Gavriil Z, et al. Selective aggregation of PAMAM dendrimer nanocarriers and PAMAM/ZnPc nanodrugs on human atheromatous carotid tissues: a photodynamic therapy for atherosclerosis. Nanoscale Res Lett. 2015;10:1–19.CrossRefGoogle Scholar
  20. 20.
    Kamalzadeh Z, Babanezhad E, Ghaffari S, Mohseni EA, Mahdieh M, Mehdi N, et al. Determination of bortezomib in API samples using hplc: assessment of enantiomeric and diastereomeric impurities. J Chromatogr Sci. 2017:1–9.Google Scholar
  21. 21.
    Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of ketoprofen. Pharmazie. 1997;52:149–51.PubMedGoogle Scholar
  22. 22.
    Agarwal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials. 2007;28:3349–59.CrossRefGoogle Scholar
  23. 23.
    Kushwah V, Agrawal AK, Dora CP. Novel gemcitabine conjugated albumin nanoparticles: a potential strategy to enhance drug efficacy in pancreatic cancer treatment. Pharm Res. 2017;34:2295–311.CrossRefGoogle Scholar
  24. 24.
    Thakkar S, Sharma D, Misra M. Comparative evaluation of electro spraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: assessment of in-vitro cytotoxicity. Eur J Pharm Sci. 2018;111:257–69.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, School of Chemical Sciences and PharmacyCentral University of RajasthanAjmerIndia
  2. 2.Centre for Pharmaceutical Nanotechnology, Department of PharmaceuticsNational Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS NagarMohaliIndia

Personalised recommendations